The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA566365
Title Role of Merlin/NF2 in mTOR Signaling and Meningioma Growth.
Publication Date Apr 2012
Media Count 19p
Personal Author A. Stemmer-Rachamimov V. Ramesh
Abstract The scope of this research project is to mechanistically define how merlin regulates mTORC1 signaling, to examine signaling downstream of mTORC2 and to validate the efficacy of mTOR inhibitors in both in vitro and in vivo preclinical models. The results obtained during assay development of an unbiased kinome screening clearly establish that Rheb is required for mTORC1 activation mediated by NF2 loss, supporting our hypothesis that NF2 may function through TSC1-TSC2 protein complex. Similar to TSC proteins, merlin negatively regulates mTORC1 and positively regulates mTORC2 However, contrary to activation of mTORC1, the attenuated mTORC2 signaling profiles exhibited by normal arachnoid and Schwann cells in response to acute merlin loss are not consistently reflected in NF2-deficient meningiomas and schwannomas, suggesting that additional genetic events may have been acquired in tumors after initial merlin loss. Our results show that mTOR kinase inhibitor such as Torin1 is more effective in blocking signaling and inhibiting proliferation of benign (WHO grdae1) and atypical (WHO grade 2) meningioma cells. A manuscript describing these results is now in press and expected to be published soon. We have shown that implantation of benign meningioma cells form tumors and may serve as valuable preclinical model for NF2.
Keywords Cells(Biology)
Clinical medicine
Genetic tissue identification
Meninges
Meningioma
Neoplasms
Nervous system diseases
Neurofibromatosis


 
Source Agency Non Paid ADAS
NTIS Subject Category 57F - Cytology, Genetics, & Molecular Biology
57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Massachusetts General Hospital, Boston.
Document Type Technical report
Title Note Annual rept. 15 Mar 2011-14 Mar 2012.
NTIS Issue Number 1307
Contract Number W81XWH-11-1-0264

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader